Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer

By LabMedica International staff writers
Posted on 20 Apr 2026

Cutaneous squamous cell carcinoma (cSCC) is the world’s second most common skin cancer, and while many cases are treatable, a subset becomes highly aggressive and therapy‑resistant. More...

Identifying molecular drivers that tip tumors toward invasion and metastasis remains a clinical priority, and understanding how epidermal identity is maintained may help flag high-risk disease earlier. New findings now identify a protein safeguard that preserves epithelial programming and limits the transition to metastatic behavior.

Hebrew University of Jerusalem researchers identified WWOX as a molecular “protein shield” that preserves epithelial identity in cSCC. The study outlines how this protein functions as a primary defense against progression to aggressive disease. Loss of WWOX was linked to transformation of common skin cancer cells into invasive, poorly differentiated forms.

Mechanistically, WWOX stabilizes the p63 protein, a master regulator that maintains epithelial structure and function. When WWOX is intact, p63 remains stable and skin cells retain their identity. When WWOX is lost, p63 levels drop, triggering epithelial‑to‑mesenchymal transition (EMT) that endows cells with migratory properties, enabling invasion and dissemination to the lungs and other organs.

Using advanced genetic models alongside human tissue samples, the investigators showed that combined loss of WWOX and the tumor suppressor p53 markedly accelerated tumor onset. Tumors arising under double deficiency were earlier, more aggressive, and poorly differentiated compared with settings in which WWOX remained functional. In these models, 100% of subjects with dual WWOX–p53 loss developed tumors, versus a much lower percentage in control groups.

Analyses of human tissue microarrays supported the translational relevance: as cSCC advanced, WWOX and p63 levels declined in tandem. According to the authors, this correlation suggests both proteins could serve as clinical biomarkers to help predict which tumors are likely to become dangerous. The findings were published in Proceedings of the National Academy of Sciences under the title “WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma.” The results further suggest that restoring WWOX, stabilizing p63, or promoting epithelial differentiation might inhibit EMT and slow tumor growth.

Related Links
Hebrew University of Jerusalem


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: The method combines metagenomic sequencing with computational filtering to identify likely disease-causing bacteria and viruses (Image Credit: iStock)

Computational Filters Enhance Metagenomic Detection of Meningitis and Encephalitis

Infections of the central nervous system, such as meningitis and encephalitis, can be severe and require prompt diagnosis and treatment. Clinicians typically evaluate cerebrospinal fluid alongside symptoms... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.